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Abstract
Background
Delirium is a serious and distressing neurocognitive condition common in people with
advanced illness. The understanding of delirium pathophysiology is limited and largely
hypothetical. To accelerate empirical understanding of delirium pathophysiology, robust
scientific methods for conducting and reporting delirium biomarker studies are urgently
needed. The aim of this study was to develop international consensus on the core elements of
high quality delirium biomarker studies.

Methods
A three-round modified Delphi survey was conducted from February to August, 2019.
Participants were international researchers experienced in conducting delirium studies from a
range of settings (hospital, university, research centres). Round one commenced with openended questions developed from results from a prior systematic review and the REMARK
checklist. Responses were qualitatively analysed and closed statements were developed.
Participants then ranked the importance of these statements using a 5-point likert scale in
rounds 2 and 3. A priori consensus was defined as ≥70% participant agreement. Descriptive
statistics for each item were computed including the mean Likert scores, standard deviation
(SD), and median participant scores.
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Results
Twenty-eight participants completed survey round one, 16 completed round two, and 19
completed the final round. Consensus was achieved for a total of 60 items.

Conclusion
The Delphi survey identified items that expert researchers agreed were important in the
conduct of delirium biomarker studies. These reporting items provide a strong platform for
improved methodological quality and opportunities to synthesise future delirium biomarker
studies.
Key words: Guidelines, Methodology, Consensus, Pathophysiology
Key points:
-

Despite the prevalence and impact of delirium, knowledge of its pathophysiology is
largely hypothetical. Better understanding of the pathophysiology of delirium is
crucial to develop more effective ways to prevent and treat delirium.

-

To understand the pathophysiology of delirium, more robust scientific methodologies
for delirium biomarker research are needed.

-

There are currently no guidelines for conducting and reporting delirium biomarker
studies, which impacts on the individual and overall quality of this body of research.
Reporting guidelines would improve the rigor of its methodology and reporting, and
increase the potential for future studies to be synthesised through meta-analyses.
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Introduction
Delirium is a serious, acute and complex neurocognitive condition that is often precipitated
by an acute medical event such as infection, or surgery. Delirium is characterized by an acute
change in attention, awareness and cognition and variously affects memory, language,
visuospatial ability, orientation and perception1. Delirium is associated with multiple adverse
clinical outcomes including high levels of patient and caregiver distress, increased morbidity,
mortality and length of hospital stay and significant costs to the healthcare system2-6. A
systematic review found delirium prevalence in medical in-patients at admission to hospital
to range between 10 and 31%, with incidence of new delirium during admission ranging from
3 to 29%. Occurrence rates for delirium per admission ranged between 11 and 42%7. Despite
the high prevalence and impact of delirium, knowledge of its pathophysiology is largely
hypothetical8. Hence, biomarker studies are crucial in this field to accelerate our
understanding of delirium biology leading to potential therapies. A biomarker is a biological
molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal
process, or of a condition or disease9.
Reporting guidelines currently exist that are relevant to biomarker studies. These are the
STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) for
reporting observational studies10, reporting guidelines for body fluid markers in neurologic
disorders11, the STARD (STAndards for the Reporting of Diagnostic accuracy)12 and the
REMARK (REporting recommendations for tumour MARKer prognostic studies)13.
However, no reporting guidelines currently exist for delirium biomarker studies, and it is not
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known how well these existing guidelines may be modified to inform optimal delirium
biomarker research.
In the absence of reporting guidelines in delirium biomarker research, we applied the
REMARK checklist,13 a reporting guideline for tumour marker prognostic studies, to assess
the quality of studies included in a recent systematic review of the overlap of delirium and
advanced cancer biomarkers (PROSPERO CRD42017068662). The review found that most
of the 151 included articles were of low quality. Unfortunately, despite the volume of studies,
their overall low quality limits the trustworthiness and impact of outcomes, comparability of
results and ability to synthesise findings to inform empirical understanding of delirium
pathophysiology. The absence of reporting guidelines for delirium biomarker studies has
likely contributed to this identified problem.
Therefore, this study aimed to obtain international consensus from leaders in delirium
research, on the core elements for high quality delirium biomarker studies, to improve our
understanding of delirium pathophysiology.

Methods
Study design
A three-round survey was employed in accordance with the Delphi method14.
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Participants
Those considered eligible were delirium researchers who had investigated delirium in
humans, including but not restricted to biomarkers. Researchers with basic science and
animal study backgrounds were also eligible if their research focus was on delirium. Expert
panel members were required to have delirium research experience in the last ten years (with
no minimum number of years pre-specified), and computer and internet access with an email
address to access the online survey. Those who met these eligibility criteria were deemed to
have adequate knowledge, expertise and opportunity to make a meaningful contribution to
the topic area.

Recruitment
A combination of purposive sampling and snowballing was used to recruit the expert
panel15,16. Purposive recruitment approaches included: 1) email invitation via membership
lists of Delirium Societies’ (Australasian Delirium Association, American Delirium Society
and the European Delirium Association); 2) email invitations through colleagues and
professional networks; and 3) researchers identified from journal articles as having
experience in delirium biomarker studies. An indirect approach included a Twitter
advertisement on the 2019 ‘World Delirium Awareness Day’17. Snowball sampling was
achieved by asking eligible participants and presidents of delirium societies to invite any
other eligible researchers who may be interested in taking part in the study, by forwarding the
invitation via email.
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Data collection
Each potential participant was sent an email invitation with a link to the online REDCap
survey in three parts: A participant information sheet outlining the study procedures and their
involvement in the study, a demographics section, and the survey questions. Non-completion
of a round did not prohibit participants from participating in the subsequent rounds.
Demographic details were collected at the beginning of each round, only once per participant.
A reminder email was sent around14 days following dissemination of each survey round.
Round 1
Round 1 aimed to generate a broad range of opinions. This round was informed by results
from the quality assessment of a prior systematic review, and predominantly used an openended qualitative method, as in the traditional approach to the Classic Delphi 16. The initial
draft survey of round 1 was piloted by three researchers with sufficient clinical understanding
of delirium and knowledge of biomarker research. These researchers were not involved in the
Delphi development and were not eligible to be study participants.
In round 1, participants were provided with both open-ended and closed questions about
biomarker research in delirium based on each key domain of the REMARK checklist13.
Participants were also invited to provide comments after each question. The answers from
round 1 informed development of a list of statements for round 2 of the Delphi.
Round 2
In round 2, 56 statements were reduced by a rating process whereby participants rated each
statement on a 5-point Likert scale from 1 (not important at all) to 5 (very important).
Participants were also invited to provide comments and suggest any alternate wording for
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each statement. Reasons for excluding comments or items suggested by participants were
recorded.
Round 3
This final round aimed to refine the final list of statements pertaining to recommendations for
reporting of delirium biomarker studies. In round 3, participants were sent the survey along
with: 1) a summary of round 2 statements that reached consensus; 2) a summary of
statements that did not reach consensus (which were repeated in this round); and 3) newly
suggested statements from participants’ comments in round 2. Group ratings were displayed
next to each statement, allowing participants to revise the collective response in a blinded
way. Participants were asked to provide a new rating on the 5-point Likert scale. Only
statements that did not achieve consensus from round 2 were carried into round 3. Round 2
statements that already achieved a consensus were excluded from round 3, but were still
presented in the summary for participants to review.

Data analysis
Round 1
Demographic data from each round was collated and inputted into the IBM Statistical
Package for Social Science (SPSS), Version 25. Round 1 open-ended responses were
compiled from Excel spreadsheets into Microsoft Word and thematically analysed by the lead
author (IAD), with two other reviewers (MA and AM) providing guidance and oversight of
the themes and codes. Reviewers discussed any uncertainties about the coding or themes until
an agreement was met. Reasons recorded for excluding or amending comments or items prior
to round 2 were that the item/comment(s) were:
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i.

too vague

ii.

a misunderstanding of the question

iii.

not relevant to the topic or study

iv.

repetitious in meaning or intent

v.

already encompassed within another item and/or or better combined with another item

Rounds 2 and 3
A target 70% agreement for the score of 4 or more on the 5-point Likert scale for each
statement was chosen a priori. REDCap data were exported to SPSS for statistical analysis.
Descriptive data for each item were obtained, including the mean Likert scores, standard
deviation (SD) and the median. Round 2 items with the greatest participant agreement in the
very low and low importance categories (Likert score 1 and 2) were deemed unlikely to be
included in the list of recommendations; items with the participant agreement in the moderate
importance category (Likert score 3) were considered for inclusion in the recommendations
and items with the greatest participant agreement in the high to very high importance
category (Likert scores ≥4), were included in the recommendations. Data analysts were
blinded to participants’ identities.
Ethical considerations
Ethical approval was obtained from the University of Technology Sydney Human Research
Ethics Committee (approval no. ETH18-2673).

Results
Participants
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Surveys were delivered over three rounds from February to August 2019 via email. Twentynine participants completed round 1, however, one participant’s data was removed as it was
clear to the authors that the questions had not been understood, and therefore the responses
were not able to be coded. Nineteen participants completed round 2, and 20 completed round
3, with a total of 32 participants completing at least one round and 10 completing all three
rounds. Participants were from 12 countries (Argentina, Australia, Belgium, Germany, Italy,
Norway, Portugal, Sweden, Switzerland, The Netherlands, United Kingdom (UK) and United
States (US)). Overall, the expert panel were predominantly clinician researchers (n=21; 64%),
with 47% of participants having over 10 years’ experience in delirium research and 47%
having conducted more than 10 delirium studies. Twenty five (78%) of participants had
conducted between 0 and 5 biomarker studies, 13% between 5 and 10, and 3 participants
(9%) had conducted over 10 biomarker studies. Twenty two (69%) had conducted a delirium
biomarker study, and nine (28%) of participants had a research higher degree in delirium and
two (6%) in biomarkers (table 1).

Insert table 1 here
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Consensus
The 18 open-ended questions and 5 closed questions of round 1 were grouped and reduced to
56 statements for round 2, with statements adjusted or removed if unclear, repetitive or
already encompassed in another statement, not relevant to topic, or better combined with
another item. An outline of the process of including items in the final delirium biomarker
recommendations is shown in figure 1. Following round 2, 51 statements reached consensus
for inclusion, and 5 statements did not. Twelve newly-suggested statements arising from
round 2 were carried into round 3, along with the 5 statements that did not reach a consensus
(n=17 items in total). Following round 3, 60 statements reached a consensus, and 8 did not.
Insert figure 1 here.
Figure 1. Flow chart illustrating the three-stage Delphi process, informed by a prior systematic review

The 60 statements that achieved a priori level of consensus for inclusion in the delirium
biomarker study reporting guidelines (i.e ≥ 70% agreement with scores 4 or 5) are shown in
table 2. Table 3 lists the 8 items that did not achieve consensus after 3 rounds of the Delphi.
No item received a score of ≤ 2 and hence were not excluded based on this criteria.

Insert Table 2 here
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Insert table 3 here
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The final list of recommendations is presented in table 4.

Insert table 4 here
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Discussion
This study presents the first set of delirium-specific recommendations to aid in the conduct
and reporting of future delirium biomarker research. Consensus was achieved in 60 items,
with a total of 8 items that did not reach a consensus. Based on open-ended findings from
round 1 and 2, consensus was not achieved on the more complex methodological aspects of
delirium biomarker research, for example, accounting for underlying diseases in patients with
delirium.
Despite a large number of emerging delirium biomarker studies, the pathophysiology of
delirium is still poorly understood. A concerted effort is required to standardise the
methodology used in delirium biomarker studies, in order to progress this fundamental field
of research. Inadequate and/or unclear reporting of methodological processes can lead to
discrepancies in results, which may be misleading and potentially detrimental 18. Reporting
guidelines are necessary to promote studies that are standardised and reported in a transparent
manner to facilitate reliable and consistent interpretation, application and synthesis of study
results. A systematic review examining the extent to which journals encourage reporting
guidelines found that nearly half of the online instructions to authors mentioned reporting
guidelines (19/41 (46%))19. Other studies have found that reporting guidelines such as the
CONSORT (Consolidated Standards of Reporting Trials) Statement20 has led to
improvements in the reporting rigor, particularly in the method of sequence generation and
the allocation concealment, compared to studies that did not adopt the CONSORT 21.
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Current guidelines that focus on different aspects of biomarkers include the REMARK,
STARD and CONSORT statements, which are used when the focus is on prognostic
biomarkers, diagnostic testing, or when conducting randomised controlled trials. However,
none of these guidelines are specific to delirium. We therefore utilised the REMARK
checklist as a framework to guide in the development of these preliminary recommendations
for guidelines. The final items illustrate areas where specific guidance was deemed useful by
international delirium experts, to specifically address methodological issues in delirium.
Three domains overlap with the REMARK checklist (assay procedures, sample size
calculation, and univariate and multivariate results) and the remainder are unique to delirium
biomarker studies.

Limitations and strengths
Several limitations of this study are worth noting. Firstly, some participants in round 1 did
not understand the questions which relied on some background knowledge in the biomarker
field. This resulted in 66 comments (66/224; 29.4%) that were excluded from round 1.
Secondly, there was noteworthy attrition between rounds, with only 10 participants
completing all three rounds. Thirdly, since delirium is a condition which often occurs in the
context of other conditions with similar pathophysiological processes, such as cancer,
complex questions with multiple competing issues that need to be considered in
methodological design are not suited to be reduced down to simple statements within a
Delphi method. This requires a more in-depth qualitative approach to identify the nuanced
methodological considerations needed. Hence the guidelines presented in this study may not
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be universal and researchers will still need to consider whether there are additional special
considerations to be considered when applying them to specific scenarios and settings.
Lastly, there is no universally agreed definition of ‘consensus’ for a Delphi. Some argue that
51% agreement on an item is acceptable22, while others maintain anywhere from 75%23 to
100% agreement amongst respondents24. It should also be noted that although the Delphi
concludes when a consensus has been achieved, the end results aren’t necessarily the most
reliable or appropriate end-product25 but rather, a majority opinion26.
Key strengths include: the systematic approach to generate the final items, drawing on both
the existing literature from a prior systematic review and expert opinion. Another key
strength of this study was the breadth of expertise within the international expert panel,
though we acknowledge that we may have not encompassed all possible perspectives. Lastly,
although there is no universal agreement of the ideal sample size for Delphi studies, most
Delphi’s have included between 15 and 20 participants, and the expertise of the panel is
considered more important that the size of the sample itself14,27,28. Considering the small
cohort of expert delirium researchers worldwide, we believe 32 participants was a sufficient
sample16.

Implications for future research and practice
This Delphi study proposes the first set of recommendations to inform development of
reporting guidelines for delirium biomarker studies, which can be refined after experience of
their utility in practice. The systematic review undertaken by the same authors demonstrated
a number of poor quality studies that were likely affected by a lack of guidelines for delirium
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biomarker research. Developing reporting guidelines was therefore an essential step to
improving methodological and reporting rigor, which will increase the potential for future
studies to be synthesised through meta-analyses. This Delphi study proposes a preliminary
list of 60 items to be considered in these reporting guidelines. To supplement these
recommendations, the authors have conducted interviews with experts in the field discussing
the key methodological issues that were more complex for which a Delphi approach was not
suited. Namely, how to account for other co-existing conditions (e.g. cancer or sepsis) that
plausibly impact on the pathophysiological and/or biological findings. Likewise, the
practicalities of obtaining biomarkers from people with delirium for research was another
issue that arose from this study which was explored in depth in a follow-up interview study.
Ongoing international collaboration will be needed to achieve a tighter consensus.

Conclusion
This study presents the first step towards development of reporting guidelines for delirium
biomarker studies through a rigorously conducted Delphi survey of international experts in
delirium research. Results will support the development of greater methodological rigor in
future delirium biomarker research, which will ultimately contribute to better understanding
of the pathophysiology of delirium.
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Table 1. Demographic characteristics of Delphi participants (n=32)

n (%)
Country of residence
USA
14 (44)
Europe
11 (34)
United Kingdom
4 (13)
Australia
2 (6)
Latin America
1 (3)
Years in delirium research
10+
15 (47)
5-10
10 (31)
0-5
7 (22)
Current role
Clinician/researcher
21 (64)
Researcher
6 (19)
Clinician
5 (15)
Place of work
Hospital
26
University
22
Research centre
8
Other
1
Main delirium research area
Clinical trials
22
Epidemiology
14
Health services
9
Implementation/knowledge
9
translation/education
Qualitative research
6
Other
2
Number of delirium studies conducted
10+
15 (47)
5-10
9 (28)
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0-5
8 (25)
Number of biomarker studies conducted
10+
3 (9)
5-10
4 (13)
0-5
25 (78)
Conducted a delirium biomarker study
Yes
22 (69)
No
10 (31)
Research higher degree (Masters or Doctorate)
In delirium
9 (28)
In biomarkers
2 (6)
Both
6 (19)
No
15 (47)
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One participant did not respond to this statement

Statement
Very
Moderately
Not
Slightly
Not
important
important
important
important
important
(5)
(4)
(2)
or
at all
(1)
unimportan
t (3)
In delirium biomarker studies, the study objective statement should at a minimum, include the following key elements:
The biomarker under study (including source)
14 (87.5)
2 (12.5)
0 (0.0)
0 (0.0)
0 (0.0)
The time of collection in relation to delirium onset 11 (68.8)
3 (18.8)
2 (12.5)
0 (0.0)
0 (0.0)
The clinical endpoint(s) including their definition
13 (81.3)
2 (12.5)
1 (6.3)
0 (0.0)
0 (0.0)
The clinical covariates
9 (45.0)
8 (40.0)
3 (15.0)
0 (0.0)
0 (0.0)
The methods of biomarker collection 1
9 (45.0)
6 (30.0)
3 (15.0)
1 (5.0)
0 (0.0)
Clarify which delirium pathophysiological theory 6 (30.0)
10 (50.0)
2 (10.0)
1 (5.0)
1 (5.0)
the study will address
The biomarker in a delirium study should be:
Chosen a priori
9 (56.3)
7 (43.8)
0 (0.0)
0 (0.0)
0 (0.0)
Supported by a biologically plausible rationale
12 (75.0)
3 (18.8)
1 (6.3)
0 (0.0)
0 (0.0)
Supported by a clear hypothesis
10 (62.5)
3 (18.8)
3 (18.8)
0 (0.0)
0 (0.0)
Putting practical considerations aside, the type of biological specimen chosen should:
Be based on the capacity to measure the proposed 7 (43.8)
9 (56.3)
0 (0.0)
0 (0.0)
0 (0.0)
biological process being evaluated
Have high specificity and sensitivity
8 (50.0)
7 (43.8)
1 (6.3)
0 (0.0)
0 (0.0)
In biomarker studies:
Delirium cases should be diagnosed by a trained
6 (37.5)
9 (56.3)
1 (6.3)
0 (0.0)
0 (0.0)
assessor or specialist doctor

Table 2. Summary of ratings for items that reached a ≥70% consensus after three Delphi rounds*

1
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4.5/5
4.6/5
4.4/5

4.8/5
4.5/5
4.6/5
4.3/4
4.2/4
3.9/4

.51

.51
.60
.81

.34
.72
.79
.73
.91
1.05

83.8% (5,4)

100% (5,4)

100% (5,4)
75% (5)
81.3% (5,4)

87.5% (5)
87.6% (5,4)
81.3% (5)
85% (5,4)
75% (5,4)
80% (5,4)

SD

4.4/4

.62

93.8% (5,4)

Total %
consensus
achieved
(category)

4.4/4.5

.77

Mean
rating/Medi
an rating

4.2/4

Delirium should be assessed using a validated
13 (81.3)
2 (12.5)
1 (6.3)
0 (0.0)
delirium diagnosis tool
Delirium should be prospectively evaluated
8 (50.0)
6 (37.5)
2 (12.5)
0 (0.0)
Adult and paediatric populations should be
8 (50.0)
5 (31.3)
2 (12.5)
1 (6.3)
considered separately
In biomarker studies, confounding variables need to:
Be decided a priori
5 (31.3)
8 (50.0)
3 (18.8)
0 (0.0)
Take into account the population being
12 (75.0)
4 (25.0)
0 (0.0)
0 (0.0)
studied/the clinical condition
Be clearly defined and justified
13 (81.3)
3 (18.8)
0 (0.0)
0 (0.0)
Be accounted for in the analysis
15 (93.8)
1 (6.3)
0 (0.0)
0 (0.0)
The minimum clinical covariates that should be taken into account in delirium biomarker studies are:
Age, gender, concurrent medication,
12 (75.0)
3 (18.8)
1 (6.3)
0 (0.0)
comorbidities, prior cognitive impairment, prior
neurological conditions, frailty, delirium risk and
delirium precipitants
Illness severity
14 (70.0)
4 (25.0)
1 (5.0)
0 (0.0)
Sepsis
6 (30.0)
9 (45.0)
3 (15.0)
2 (10.0)
Inflammation
7 (35.0)
10 (50.0)
1 (5.0)
2 (10.0)
The following control groups are appropriate in a delirium biomarker study:
Participants without delirium
10 (62.5)
5 (31.3)
1 (6.3)
0 (0.0)
As delirium is a complex clinical condition with
7 (35.0)
7 (35.0)
3 (15.0)
3 (15.0)
many influencing clinical variables several
control groups will strengthen the ability to
interpret the findings
Same illness severity with and without delirium
9 (45.0)
8 (40.0)
2 (10.0)
1 (5.0)
Delirium superimposed on dementia
6 (30.0)
8 (40.0)
3 (15.0)
1 (5.0)
In studies which follow participants longitudinally, appropriate additional comparator groups are:
Participants with delirium of a shorter duration
4 (25.0)
8 (50.0)
3 (18.8)
1 (6.3)
Participants who do not develop delirium
10 (62.5)
4 (25.0)
1 (6.3)
1 (6.3)
Delirium biomarker studies should support the person with delirium and their proxy decision maker by:
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0 (0.0)
0 (0.0)

0 (0.0)
1 (5.0)

0 (0.0)
0 (0.0)

0 (0.0)
0 (0.0)
0 (0.0)

0 (0.0)

0 (0.0)
0 (0.0)

0 (0.0)
0 (0.0)

0 (0.0)
0 (0.0)

0 (0.0)

3.9/4
4.4/5

4.2/4
3.7/4

4.5/5
3.9/4

4.6/5
3.9/4
4.1/4

4.7/5

4.8/5
4.9/5

4.1/4
4.7/5

4.4/4.5
4.2/4.5

4.6/5

.85
.89

1.0
1.2

.81
1.07

.58
.94
.91

.60

.40
.50

.71
.44

.71
.93

1.02

75% (5,4)
87.5% (5,4)

85% (5,4)
70% (5,4)

93.8% (5,4)
70% (5,4)

70% (5))
75% (5,4)
85% (5,4)

75% (5)

81.3% (5)
93.8% (5)

81.3% (5,4)
75% (5)

87.5% (5,4)
81.3% (5,4)

81.3% (5)

Clear participant information that explains the
11 (68.8)
4 (25.0)
study to the person with delirium and/or their
proxy decision maker
Clear procedures to assist staff in interacting and
12 (75.0)
2 (12.5)
supporting the patient during biomarker collection
and other data collection
The value of the research in lay terms and how it
12 (75.0)
3 (18.8)
can contribute to the understanding of delirium
Having clear processes for informed consent
12 (75.0)
3 (18.8)
Description of the assay procedure should include the following as a minimum:
A detailed assay protocol that includes the
11 (68.8)
2 (12.5)
reagents/kits used
An assay validation for assay repeatability and
6 (37.5)
6 (37.5)
robustness
The inter- and intra- assay coefficients of
7 (43.8)
5 (31.3)
variation
Methods of preservation, storage and processing
11 (68.8)
3 (18.8)
of the biological sample
The assay validity
8 (50.0)
7 (43.8)
The sensitivity limits of the assay
9 (56.3)
6 (37.5)
A scoring and reporting protocol
8 (50.0)
6 (37.5)
In biomarker studies:
Blinding of the assay is essential if the clinical
12 (75.0)
2 (12.5)
outcome is subjective
Method of blinding should be explicit
9 (56.3)
4 (25.0)
Please indicate your level of agreement with the following statements
Timing of the sample collection should be
6 (37.5)
8 (50.0)
determined based on the clinical scenario
Timing of the sample collection should be
12 (75.0)
3 (18.8)
determined based on the hypothesis being tested
1 (6.3)

2 (12.5)

2 (12.5)

1 (6.3)

1 (6.3)
1 (6.3)
2 (12.5)

1 (6.3)

2 (12.5)

3 (18.8)

2 (12.5)

1 (6.3)

1 (6.3)

2 (12.5)

1 (6.3)

0 (0.0)

0 (0.0)

1 (6.3)

1 (6.3)

0 (0.0)
0 (0.0)
0 (0.0)

1 (6.3)

2 (12.5)

1 (6.3)

1 (6.3)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)
0 (0.0)
0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

4.7/5

4.2/4

4.3/5

4.6/5

4.4/4.5
4.4/5
4.4/4.5

4.5/5

4.0/4

4.0/4

4.4/5

4.6/5

4.6/5

4.6/5

4.6/5

.60

.68

.94

.89

.62
.81
.71

.89

1.06

.92

.96

.80

.80

.71

.81

75% (5)

87.5% (5,4)

81.3% (5,4)

75% (5)

93.8% (5,4)
93.8% (5,4)
87.5% (5,4)

87.6% (5,4)

75.6% (5,4)

75% (5,4)

81.3% (5,4)

75% (5)

75% (5)

75% (5)

93.8% (5,4)
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In longitudinal sampling of populations AT RISK 9 (56.3)
7 (43.8)
0 (0.0)
0 (0.0)
0 (0.0)
OF DELIRIUM, it is recommended that samples
are collected prior to delirium onset, during
delirium episode, and after delirium resolution
In longitudinal sampling of populations WITH
6 (37.5)
8 (50.0)
1 (6.3)
1 (6.3)
0 (0.0)
DELIRIUM, it is recommended that samples are
collected at delirium onset and again after
delirium resolution
Please indicate your level of agreement with the following statements on sample size in a delirium biomarker study.
Sample size should be decided a priori based on
6 (37.5)
7 (43.8)
2 (12.5)
1 (6.3)
0 (0.0)
previous studies/pilot data
Sample size should be determined based on the
8 (50.0)
6 (37.5)
2 (12.5)
0 (0.0)
0 (0.0)
estimated effect size of the biomarker in
predicting the outcome
The analysis plan should plan for clinical and biomarker missing data due to:
Clinical issues such as overall deterioration,
11 (68.8)
5 (31.3)
0 (0.0)
0 (0.0)
0 (0.0)
worsening cognition, and death
Practical challenges of biomarker collection in
12 (75.0)
4 (25.0)
0 (0.0)
0 (0.0)
0 (0.0)
people with delirium
Univariate analyses of biomarker and clinical endpoints of interest should report the following:
Estimated effect size
6 (37.5)
7 (43.8)
1 (6.3)
0 (0.0)
2 (12.5)
Whether biomarker result was dichotomised using 11 (68.8)
3 (18.8)
1 (6.3)
0 (0.0)
1 (6.3)
a cut-point and/or threshold
How missing data were handled
12 (75.0)
2 (12.5)
1 (6.3)
0 (0.0)
1 (6.3)
Number of included participants
14 (87.5)
1 (6.3)
0 (0.0)
0 (0.0)
1 (6.3)
Multivariate analyses of biomarker and clinical endpoints of interest should report the following:
Estimated effect size
8 (50.0)
8 (50.0)
0 (0.0)
0 (0.0)
0 (0.0)
Whether biomarker result was dichotomised using 11 (68.8)
5 (31.3)
0 (0.0)
0 (0.0)
0 (0.0)
a cut-point and/or threshold
How model assumptions were verified
10 (62.5)
5 (31.3)
1 (6.3)
0 (0.0)
0 (0.0)
How missing data were handled
12 (75.0)
3 (18.8)
1 (6.3)
0 (0.0)
0 (0.0)
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5.6/5
4.7/5

4.5/4.5
4.7/5

4.5/5
4.7/5

3.9/4
4.4/5

4.8/5

4.7/5

4.4/4.5

4.1/4

4.2/4

4.6/5

.62
.60

.51
.47

1.09
1.01

1.2
1.09

.44

.47

.71

.88

.83

.51

93.8% (5,4)
75% (5)

100% (5,4)
100% (5,4)

75% (5))
87.5% (5)

81.3% (5,4)
87.6% (5,4)

75% (5)

100% (5,4)

87.5% (5,4)

81.3% (5,4)

87.5% (5,4)

100% (5,4)

Number of included participants
Covariates (including how they were defined)

15 (93.8)
14 (87.5)

1 (6.3)
2 (12.5)

*Red coloured items indicate those that arose from participant suggestions/comments

0 (0.0)
0 (0.0)

Table 3. Summary of ratings for items that did NOT reach a consensus after three rounds of Delphi*

0 (0.0)
0 (0.0)
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0 (0.0)
0 (0.0)

4.9/5
4.9/5

.25
.34

93.8% (5)
87.5% (5)

Statement
Very
Moderately
Not
Slightly
Not
important
important
important or
important
important at
unimportant
all
The following control groups are appropriate in a delirium biomarker study:
Healthy participants matched by 3 (15.0)
8 (40.0)
3 (15.0)
5 (25.0)
1 (5.0)
baseline characteristics such as
age and gender
Participants with dementia,
4 (20.0)
9 (45.0)
5 (25.0)
1 (5.0)
1 (5.0)
without delirium
In studies which follow participants longitudinally, an appropriate additional comparator group is:
Participants with less severe
3 (15.0)
6 (30.0)
8 (40.0)
3 (15.0)
0 (0.0)
delirium
Description of the assay procedure should include:
Information about where the kit 4 (20.0)
9 (45.0)
4 (20.0)
3 (15.0)
0 (0.0)
was purchased and whether it
was commercially available
The minimum clinical covariates that should be taken into account in delirium biomarker studies are:
Ethnicity/race
3 (15.0)
6 (30.0)
6 (30.0)
3 (15.0)
2 (10.0)
Education 2
4 (20.0)
9 (45.0)
3 (15.0)
1 (10.0)
1 (5.0)
Psychiatric history
4 (20.0)
8 (40.0)
4 (20.0)
2 (10.0)
2 (10.0)
Injuries
3 (15.0)
10 (50.0)
6 (30.0)
1 (5.0)
0 (0.0)

One participant did not respond to this statement

*Round 3 results shown in this table
Red coloured items indicate those that arose from participant suggestions/comments.

2
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3.2/3.0
3.6/4.0
3.5/4.0
3.7/4.0

3.7/4.0

3.4/3.0

3.7/4.0

3.3/4.0

Mean
rating/Media
n rating

1.20
1.10
1.23
.78

.97

.94

1.03

1.18

SD

Table 4. The final list of recommendations for delirium biomarker studies

The study objective should include the following:
The biomarker under study (including source)
The time of collection in relation to delirium onset
The clinical endpoint(s) including their definition

The clinical covariates
The methods of biomarker collection
A description of which delirium pathophysiological theory the study will address
In defining the population:
Delirium cases should be diagnosed by a trained assessor or specialist doctor
Delirium should be assessed using a validated delirium diagnosis tool
Delirium should be prospectively evaluated
Adult and paediatric populations should be considered separately
Delirium biomarker studies should support the person with delirium and their proxy decision maker by:
Providing a clear participant information that explains the study to the person with delirium and/or their proxy decision maker
Providing clear procedures to assist staff in interacting and supporting the patient during biomarker collection and other data collection
Explaining the value of the research in lay terms and how it can contribute to the understanding of delirium
Clear processes for informed consent
When selecting control(s) group: study:
1. As delirium is a complex clinical condition with many influencing clinical variables several control groups will strengthen the ability to interpret the findings
2. The following control groups would be appropriate to consider
a. Participants without delirium
b. Participants with the same illness severity, with and without delirium
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c. Participants with delirium superimposed onto dementia
3. In studies which follow participants longitudinally, the following are appropriate additional comparator groups:
a. Participants with delirium of a shorter duration
b. Participants who do not develop delirium
The biomarker in a delirium study should be:
Chosen a priori
Supported by a biologically plausible rationale
Supported by a clear hypothesis
The type of biological specimen chosen should:
Be based on the capacity to measure the proposed biological process being evaluated
Have high specificity and sensitivity
Description of the assay procedure should include the following as a minimum:
A detailed assay protocol that includes the reagents/kits used
An assay validation for assay repeatability and robustness
The inter- and intra- assay coefficients of variation
Methods of preservation, storage and processing of the biological sample
The assay validity
The sensitivity limits of the assay
A scoring and reporting protocol
Blinding of the assay is essential if the clinical outcome is subjective
Method of blinding should be explicit
In biomarker studies, confounding variables need to:
Be decided a priori
Take into account the population being studied/the clinical condition
Be clearly defined and justified
Be accounted for in the analysis
The minimum clinical covariates that should be taken into account are:
Age, gender, concurrent medication, comorbidities, prior cognitive impairment, illness severity, sepsis, prior neurological conditions, frailty, inflammation, delirium risk and delirium
precipitants
Timing of collection
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Timing of the sample collection should be determined based on the clinical scenario and/or the hypothesis being tested
In longitudinal sampling of populations AT RISK OF DELIRIUM, it is recommended that samples are collected prior to delirium onset, during delirium episode, and after delirium
resolution
In longitudinal sampling of populations WITH DELIRIUM, it is recommended that samples are collected at delirium onset and again after delirium resolution
Sample size
Sample size should be decided a priori based on previous studies/pilot data
Sample size should be determined based on the estimated effect size of the biomarker in predicting the outcome
The analysis plan should plan for clinical and biomarker missing data due to:
Clinical issues such as overall deterioration, worsening cognition, and death
Practical challenges of biomarker collection in people with delirium
Univariate analyses of biomarker and clinical endpoints of interest should report the following:
Estimated effect size
Whether biomarker result was dichotomised using a cut-point and/or threshold
How missing data were handled
Number of included participants
Multivariate analyses of biomarker and clinical endpoints of interest should report the following:
Estimated effect size
Whether biomarker result was dichotomised using a cut-point and/or threshold
How model assumptions were verified
How missing data were handled
Number of included participants
Covariates (including how they were defined)
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